Prediction of early death among patients (pts) enrolled in phase I trials: Development and validation of a new model based on platelet count and albumin level.

2540 Background: Selecting pts with “sufficient life expectancy” for phase I oncology trials remains challenging. The Royal Marsden Model (RMM; Arkenau, JCO 2009) identified high-risk pts as those ...